Forced degradation studies are essential to the successful development of monoclonal antibodies (mAbs), bispecifics, and other biologics.

Summary: Catalent’s SMARTag® Technology offers a versatile and innovative platform for the development of optimized antibody-drug conjugates (ADCs).

Abstract: In the iPSC derived cell therapy world, developing a suitable iPSC line is a key step, but not the only one.

This webinar will bring together industry leaders to discuss innovative strategies and practical solutions for manufacturing protein-based modality therapies.

Forced degradation studies are crucial for developing recombinant monoclonal antibody therapeutics, aiding in everything from early manufacturability checks to comparability assessments before and after marketing approval.

Join Vincy Abraham, Director of Biologics Analytical Services, to discover how Catalent leverages its extensive expertise and capabilities to deliver tailored solutions to meet specific analytical needs for your biotherapeutics.

Summary: Catalent has successfully addressed the challenges associated with plasmid DNA manufacturing by developing robust process and analytical platforms. Catalent’s approach involves a one-process-fits-all single-use (SU) manufacturing process in compliance with current good manufacturing practices (cGMP) standards.

Summary: Catalent offers extensive expertise in the bioproduction of plasmid DNA, from early stages of development to CGMP manufacturing to satisfy clinical and commercial needs.

This year, the long-awaited FDA draft guidance for Platform Technology Designation Program was launched. This critical guidance allows drug developers to leverage Platform Technology data in approved drugs if similar “platforms” are used, accelerating the approval process and therapies to patients. In this webinar, George Buchman will discuss Catalent’s approach to platform processes as well as securing an integrated supply chain.

In this webinar learn how the GPEx® Lightning platform accelerates the high-titer production of next-generation multispecific antibodies and complex protein biologics